<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1519">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05141383</url>
  </required_header>
  <id_info>
    <org_study_id>IC 2021-04</org_study_id>
    <nct_id>NCT05141383</nct_id>
  </id_info>
  <brief_title>Comparative Study of Diagnostic and Prognosis Biomarkers of Prostate Cancer in Liquid Biopsy</brief_title>
  <acronym>HOPE</acronym>
  <official_title>Comparative Study of Diagnostic and Prognosis Biomarkers of Prostate Cancer in Liquid Biopsy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Curie</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Curie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Constitution of a biological collection within the framework of the establishment of a&#xD;
      diagnostic, prognostic and active surveillance test for prostate cancer from long non-coding&#xD;
      RNA biomarkers, in 3 cohorts of patients, with cancer of the prostate, with suspected cancer&#xD;
      without biopsy confirmation or with prostatic hyperplasia and healthy donors.&#xD;
&#xD;
      This biological collection will also be used as a support for further researches on the&#xD;
      identification of biomarkers and genetic markers to improve the prognosis and diagnostic&#xD;
      management of patients with prostate pathologies.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multicenter, RIPH 2 study, evaluating on 3 patient cohorts the feasibility of setting up a&#xD;
      diagnostic test, prognosis and active surveillance of prostate cancer using long non-coding&#xD;
      RNA biomarkers.&#xD;
&#xD;
      For patients agreeing to participate in the study and having signed a consent form, during&#xD;
      their routine care consultation in the urology department, will have a blood sample and a&#xD;
      urine sample after prostate massage as part of the study, and if necessary, a tissue sample&#xD;
      as part of the treatment.&#xD;
&#xD;
      Patients with prostate cancer will be followed as part of their care at least annually, and&#xD;
      their follow-up data will be collected as part of the study, without additional sampling.&#xD;
&#xD;
      A blood sample and a urine sample after prostate massage will be carried out during a single&#xD;
      consultation at the CIC Henri Mondor for&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 15, 2021</start_date>
  <completion_date type="Anticipated">January 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 15, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>3 cohorts will be included in the study:&#xD;
40 patients with prostate cancer, or&#xD;
40 patients with suspected cancer without confirmation on biopsy, or with hyperplasia of the prostate and&#xD;
38 healthy donors.</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Extracting extravesicular particles and RNA from urine fluids</measure>
    <time_frame>Baseline</time_frame>
    <description>Criteria will be a minimum of 10ng of total RNA extracted per sample total RNA sequencing and greater than 10 million unique reads mapping to the Gencode V32 reference genome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Extracting extravesicular particles and RNA from blood</measure>
    <time_frame>Baseline</time_frame>
    <description>Criteria will be a minimum of 10ng of total RNA extracted per sample total RNA sequencing and greater than 10 million unique reads mapping to the Gencode V32 reference genome.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">118</enrollment>
  <condition>Prostate Cancer</condition>
  <condition>Healthy Donors</condition>
  <arm_group>
    <arm_group_label>Patients with prostate cancer</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients with suspected prostate cancer (MRI or digital rectal examination), or prostatic hyperplasia with a PSA level&gt; 4 ng / ml</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with suspected cancer without confirmation on biopsy, or with hyperplasia of the prostate</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients with suspected prostate cancer (MRI or digital rectal examination), or prostatic hyperplasia with a PSA level&gt; 4 ng / ml</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy donors</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Male from 50 to 70 years old with a PSA level &lt;4 ng / mL</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Urine sampling</intervention_name>
    <description>A blood sample and a urine sample after prostate massage will be carried out at baseline</description>
    <arm_group_label>Healthy donors</arm_group_label>
    <arm_group_label>Patients with prostate cancer</arm_group_label>
    <arm_group_label>Patients with suspected cancer without confirmation on biopsy, or with hyperplasia of the prostate</arm_group_label>
    <other_name>Blood sampling</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Concerning patients:&#xD;
&#xD;
          1. / Patients with suspected prostate cancer (MRI or digital rectal examination), or&#xD;
             prostatic hyperplasia with a PSA level&gt; 4 ng / ml&#xD;
&#xD;
          2. / Patients with cancer detected after biopsy including 3 groups of 10 patients with&#xD;
             Gleason score&gt; = 8 (High Risk), 7 (intermediate Risk), or &lt;= 6 (low risk)&#xD;
&#xD;
          3. / Patients diagnosed by prostate MRI in the course of treatment&#xD;
&#xD;
          4. / Information of the patient and signature of informed consent or his legal&#xD;
             representative.&#xD;
&#xD;
          5. / Participant affiliated to a social security scheme&#xD;
&#xD;
        Regarding healthy volunteers:&#xD;
&#xD;
          1. / Male from 50 to 70 years old&#xD;
&#xD;
          2. / PSA level &lt;4 ng / mL&#xD;
&#xD;
          3. / No infectious episode in the week before the visit (in particular no urinary tract&#xD;
             infection), documented by dipstick and the absence of fever&#xD;
&#xD;
          4. / Absence of cancer and history of haematological pathologies (in particular leukemia,&#xD;
             lymphoma).&#xD;
&#xD;
          5. / Patient information and signature of consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        1 / Participants who refused to participate in the biological collection 2) Persons&#xD;
        deprived of their liberty or under guardianship. 3) Inability to undergo medical monitoring&#xD;
        of the trial for geographical, social or psychological reasons.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Prostate cancer or suspicion of prostate cancer</gender_description>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yves ALLORY, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Curie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sandra NESPOULOUS</last_name>
    <phone>+331 56 24 56 30</phone>
    <email>drci.promotion@curie.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Antonin MORILLON, PhD</last_name>
    <phone>+331 56 24 56 30</phone>
    <email>drci.promotion@curie.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris</city>
        <zip>75005</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Marie-Emmanuelle LEGRIER, PhD</last_name>
      <phone>+331 44 32 40 00.</phone>
      <email>drci.promotion@curie.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 19, 2021</study_first_submitted>
  <study_first_submitted_qc>November 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 2, 2021</study_first_posted>
  <last_update_submitted>November 19, 2021</last_update_submitted>
  <last_update_submitted_qc>November 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>diagnostic</keyword>
  <keyword>prognosis</keyword>
  <keyword>prostate cancer</keyword>
  <keyword>long non-coding RNA biomarkers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

